SynthesisPloS one2025
Comparative effectiveness of adjuvant treatment for hepatocellular carcinoma with high risk of recurrence: A systematic review and network meta-analysis.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify the most effective postoperative intervention regimen for persons with hepatocellular carcinoma (HCC) at high risk of recurrence.
methodsA network meta-analysis was conducted by collecting eligible studies from Medline, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science databases. Pairwise and network meta-analyses were applied to pooled data on overall survival (OS) and recurrence-free survival (RFS).
results35 studies involving 6,372 patients were analyzed. Pairwise meta-analysis showed higher OS (HR = 0.64, 95% CI: 0.56-0.72; P < 0.001; I2 = 70.9%, random effects model) and RFS (HR = 0.62, 95%CI 0.56-0.70; P < 0.001; I2 = 60.2%, random effects model) in the adjuvant intervention group compared to surgery alone. ICIs&TKIs (SUCRA = 87.3%) was significantly more effective for OS, and TKIs&TACE (SUCRA = 84.1%) was significantly more effective for RFS.
conclusionsReasonable postoperative intervention regimens can reduce recurrence risk and improve prognosis. ICIs&TKIs and TKIs&TACE are likely the two most effective adjuvant intervention regimens for individuals with HCC who are at high risk of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.